Home / Journals / OR / Vol.28, No.7-8, 2020
  • Open Access

    ARTICLE

    Curcumol Inhibits Lung Adenocarcinoma Growth and Metastasis via Inactivation of PI3K/AKT and Wnt/β-Catenin Pathway

    Sheng Li*1, Guoren Zhou*1, Wei Liu, Jinjun Ye, Fangliang Yuan, Zhi Zhang
    Oncology Research, Vol.28, No.7-8, pp. 685-700, 2020, DOI:10.3727/096504020X15917007265498
    Abstract Curcumol (Cur), isolated from the Traditional Chinese Medical plant Rhizoma Curcumae, is the bioactive component of sesquiterpene reported to possess antitumor activity. However, its bioactivity and mechanisms against lung adenocarcinoma are still unclear. We investigated its effect on lung adenocarcinoma and elucidated its underlying molecular mechanisms. In vitro, Cur effectively suppressed proliferation, migration, and invasion of lung adenocarcinoma cells A549 and H460, which were associated with the altered expressions of signaling molecules, including p-AKT, p-PI3K, p-LRP5/6, AXIN, APC, GSK3 and p- -catenin, matrix metalloproteinase (MMP)-2, and MMP-9. Furthermore, Cur significantly induced cell apoptosis of A549 and H460 by promoting the… More >

  • Open Access

    ARTICLE

    Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy

    Ching-Wen Huang*, Cheng-Jen Ma*†, Wei-Chih Su*, Yi-Ting Chen‡§, Hsiang-Lin Tsai, Yung-Sung Yeh*#, Tsung-Kun Chang*, Wen-Hung Hsu**††, Fang-Jung Yu**††, Jaw-Yuan Wang*¶‡‡§§¶¶##
    Oncology Research, Vol.28, No.7-8, pp. 701-714, 2020, DOI:10.3727/096504020X15986099915822
    Abstract This study evaluated the survival effects of metronomic maintenance therapy with oral fluoropyrimidine in patients with stage III colorectal cancer (CRC) according to epidermal growth factor receptor (EGFR) expression. We enrolled 197 patients with stage III CRC who had undergone radical resection and FOLFOX regimen adjuvant chemotherapy. The clinicopathological features and effects of metronomic maintenance therapy with oral capecitabine (daily dose of 850 mg/m2 , twice daily, on days 1–14 every 3 weeks for 6 months) on survival according to treatment group and EGFR expression were analyzed. By conducting an in vitro cell line study and in vivo study through… More >

  • Open Access

    ARTICLE

    Identification of a Novel Cancer Stemness-Associated ceRNA Axis in Lung Adenocarcinoma via Stemness Indices Analysis

    Pihua Han*†1, Haiming Yang‡1, Xiang Li*1, Jie Wu*, Peili Wang§, Dapeng Liu*, Guodong Xiao, Xin Sun*, Hong Ren*
    Oncology Research, Vol.28, No.7-8, pp. 715-729, 2020, DOI:10.3727/096504020X16037124605559
    Abstract The aim of this study was to identify a novel cancer stemness-related ceRNA regulatory axis in lung adenocarcinoma (LUAD) via weighted gene coexpression network analysis of a stemness index. The RNA sequencing expression profiles of 513 cancer samples and 60 normal samples were obtained from the TCGA database. Differentially expressed mRNAs (DEmRNAs), lncRNAs (DElncRNAs), and miRNAs (DEmiRNAs) were identified with R software. Functional enrichment analysis was conducted using DAVID 6.8. The ceRNA network was constructed via multiple bioinformatics analyses, and the correlations between possible ceRNAs and prognosis were analyzed using Kaplan–Meier plots. WGCNA was then applied to distinguish key genes… More >

  • Open Access

    ARTICLE

    miR-325-3p Promotes the Proliferation, Invasion, and EMT of Breast Cancer Cells by Directly Targeting S100A2

    Huiling Wang*, Xin Hu, Feng Yang, Hui Xiao*
    Oncology Research, Vol.28, No.7-8, pp. 731-744, 2020, DOI:10.3727/096504020X16100888208039
    Abstract This study was designed to investigate the precise mechanisms of miR-325-3p/S100A2 axis in breast cancer (BC). In this study, we found that the level of miR-325-3p was dramatically increased in BC tissues and cell lines, and the expression of S100A2 was significantly decreased. Also, the high level of miR-325-3p was closely associated with low expression of S100A2 in BC tissues. Moreover, introduction of miR-325-3p significantly promoted proliferation, invasion, and EMT of BC cells. Bioinformatics analysis predicted that the S100A2 was a potential target gene of miR-325-3p. Luciferase reporter assay demonstrated that miR-325-3p could directly target S100A2. In addition, miR-325-3p overexpression… More >

  • Open Access

    ARTICLE

    Therapeutic Targeting PLK1 by ON-01910.Na Is Effective in Local Treatment of Retinoblastoma

    Huan Ma1, Cong Nie1, Ying Chen, Jinmiao Li, Yanjie Xie, Zhixin Tang, Yang Gao, Siming Ai, Yuxiang Mao, Qian Sun, Rong Lu
    Oncology Research, Vol.28, No.7-8, pp. 745-761, 2020, DOI:10.3727/096504021X16130322409507
    Abstract Cell cycle deregulation is involved in the pathogenesis of many cancers and is often associated with protein kinase aberrations, including the polo-like kinase 1 (PLK1). We used retinoblastoma, an intraocular malignancy that lacks targeted therapy, as a disease model and set out to reveal targetability of PLK1 with a small molecular inhibitor ON-01910.Na. First, transcriptomic analysis on patient retinoblastoma tissues suggested that cell cycle progression was deregulated and confirmed that PLK1 pathway was upregulated. Next, antitumor activity of ON-01910.Na was investigated in both cellular and animal levels. Cytotoxicity induced by ON-01910.Na was tumor specific and dose dependent in retinoblastoma cells,… More >

  • Open Access

    ARTICLE

    (−)-Epigallocatechin-3-Gallate Inhibits EBV Lytic Replication via Targeting LMP1-Mediated MAPK Signal Axes

    Hongde Li*†‡, Yueshuo Li*†‡, Jianmin Hu*†‡, Sufang Liu§, Xiangjian Luo*†‡¶, Min Tang*†‡, Ann M. Bode#, Zigang Dong#**, Xinqi Liu††, Weihua Liao‡‡, Ya Cao*†‡¶ §§¶¶
    Oncology Research, Vol.28, No.7-8, pp. 763-778, 2020, DOI:10.3727/096504021X16135618512563
    Abstract Epstein–Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) plays an important oncogenic role in the viral latent infection. Recently, increasing evidence indicates that the high expression of LMP1 during EBV lytic cycle is related to the viral lytic replication. However, the mechanism by which LMP1 regulates EBV lytic replication remains unclear. (−)-Epigallocatechin-3-gallate (EGCG) prevents carcinogenesis by directly targeting numerous membrane proteins and effectively inhibits EBV lytic cascade. Here, we demonstrated that LMP1 promotes EBV lytic replication through the downstream signal molecules MAPKs, including ERKs, p38, and JNKs. LMP1 induces the phosphorylation of p53 through MAPKs to enhance the ability of… More >

  • Open Access

    ARTICLE

    TBK1 Inhibitor Exerts Antiproliferative Effect on Glioblastoma Multiforme Cells

    Sarah A. Scuderi*, Marika Lanza*, Giovanna Casili*, Francesca Esposito, Cristina Colarossi, Dario Giuffrida, Paterniti Irene*, Salvatore Cuzzocrea*,* Emanuela Esposito*, Michela Campolo*
    Oncology Research, Vol.28, No.7-8, pp. 779-790, 2020, DOI:10.3727/096504021X16161478258040
    Abstract Glioma are common malignant brain tumors, among which glioblastoma multiforme (GBM) has the worst prognosis. Different studies of GBM revealed that targeting nuclear factor B (NF- B) induced an attenuation tumor proliferation and prolonged cell survival. TBK1 {TANK [TRAF (TNF (tumor-necrosis-factor) receptorassociated factor)-associated NF- B activator]-binding kinase 1} is a serine/threonine protein kinase, and it is a member of the I B kinase (IKK) family involved in NF- B pathway activation. The aim of this study was to investigate the potential effect of BX795, an inhibitor of TBK1, in an in vitro and ex vivo model of GBM. GBM cell… More >

  • Open Access

    ARTICLE

    Excellent Early Outcomes of Combined Chemotherapy With Arsenic Trioxide for Stage 4/M Neuroblastoma in Children: A Multicenter Nonrandomized Controlled Trial

    Chunmou Li*1, Xiaomin Peng*1, Chuchu Feng*1, Xilin Xiong*, Jianxin Li, Ning Liao, Zhen Yang§, Aiguo Liu, Pingping Wu*, Xuehong Liang, Yunyan He, Xin Tian§, Yunbi Lin§, Songmi Wang, Yang Li*
    Oncology Research, Vol.28, No.7-8, pp. 791-800, 2020, DOI:10.3727/096504021X16184815905096
    Abstract This nonrandomized, multicenter cohort, open-label clinical trial evaluated the efficacy and safety of combined chemotherapy with arsenic trioxide (ATO) in children with stage 4/M neuroblastoma (NB). We enrolled patients who were newly diagnosed with NB and assessed as stage 4/M and received either traditional chemotherapy or ATO combined with chemotherapy according to their own wishes. Twenty-two patients were enrolled in the trial group (ATO combined with chemotherapy), and 13 patients were enrolled in the control group (traditional chemotherapy). Objective response rate (ORR) at 4 weeks after completing induction chemotherapy was defined as the main outcome, and adverse events were monitored… More >

  • Open Access

    ARTICLE

    A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab

    Tsung-Kun Chang*†, Tzu-Chieh Yin‡§, Wei-Chih Su*†, Hsiang-Lin Tsai, Ching-Wen Huang, Yen-Cheng Chen*, Ching-Chun Li*, Po-Jung Chen*, Cheng-Jen Ma, Kuo-Hsiang Chuang#, Tian-Lu Cheng**, Jaw-Yuan Wang*†¶††‡‡§§
    Oncology Research, Vol.28, No.7-8, pp. 801-809, 2020, DOI:10.3727/096504021X16218531628569
    Abstract Irinotecan, a topoisomerase inhibitor, is a common cytotoxic agent prescribed for metastatic colorectal cancer (mCRC) patients. Diarrhea is the most common adverse event (AE). The underlying mechanism of irinotecaninduced diarrhea is intestinal mucosal damage caused by SN-38 (active metabolite of irinotecan) hydrolyzed from SN-38G (inactive metabolite) by bacterial -glucuronidase ( G). According to an animal study, silymarin reduces the activity of bacterial G without impairing antitumor efficacy. We conducted a prospective openlabel pilot study to evaluate the effect of silymarin as supplementation in reducing toxicities of mCRC patients undergoing irinotecan-based chemotherapy. We enrolled and randomized 70 mCRC patients receiving first-line… More >

  • Open Access

    BRIEF COMMUNICATION

    Outcomes of Patients With Acute Myeloid Leukemia Who Relapse After 5 Years of Complete Remission

    Arisha Patel, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Robert L. Redner, Annie Im, Kathleen A. Dorritie, Alison Sehgal, James Rossetti, Melissa Saul, Daniel Normolle, Konstantinos Lontos, Michael Boyiadzis
    Oncology Research, Vol.28, No.7-8, pp. 811-814, 2020, DOI:10.3727/096504020X15965357399750
    Abstract Leukemia relapse 5 years after achieving first complete remission (CR1) is uncommon in patients with acute myeloid leukemia (AML). In this study, we evaluated the outcomes of AML patients with late relapse at our institution and reviewed the literature for these patients. The study cohort consisted of nine AML patients with late relapse. The median interval between CR1 and AML relapse was 6.1 years (range: 5.1–16.2 years). At relapse, the karyotype was different from the initial AML diagnosis in 50% of patients. At the time of AML relapse, seven patients received induction chemotherapy and two patients received hypomethylating agents with… More >

  • Open Access

    ERRATUM

    Inhibition of Beclin-1-Mediated Autophagy by MicroRNA-17-5p Enhanced the Radiosensitivity of Glioma Cells

    Weichen Hou*, Lei Song, Yang Zhao*, Qun Liu*, Shuyan Zhang
    Oncology Research, Vol.28, No.7-8, pp. 815-818, 2020, DOI:10.3727/096504021X16240202939988
    Abstract The role of miRNAs in the radiosensitivity of glioma cells and the underlying mechanism is still far from clear. In the present study, we detected six downregulated and seven upregulated miRNAs in the serum after radiotherapy compared with paired serum samples before radiotherapy via miRNA panel PCR. Among these, miR-17-5p was highly reduced (fold change = −4.21). Further, we validated the levels of miR-17-5p in all serum samples with qRT-PCR. In addition, statistical analysis suggested that a reduced miR-17-5P level was positively associated with advanced clinical stage of glioma, incidence of relapse, and tumor differentiation. Moreover, we provided evidence that… More >

  • Open Access

    ERRATUM

    MicroRNA-133a Inhibits Proliferation of Gastric Cancer Cells by Downregulating ERBB2 Expression

    Chang Li*, Xiaoping Li, Shuohui Gao*, Chang Li, Lianjun Ma§
    Oncology Research, Vol.28, No.7-8, pp. 819-822, 2020, DOI:10.3727/096504021X16240202940003
    Abstract Gastric cancer is the fourth most common type of cancer and the second highest leading cause of cancer-related deaths worldwide. It has already been established that miR-133a is involved in gastric cancer. In this study, we investigated the molecular mechanisms by which miR-133a inhibits the proliferation of gastric cancer cells. We analyzed the proliferative capacity of human gastric cancer cells SNU-1 using an MTT assay. Cell apoptosis was determined using flow cytometry. The expression levels of ERBB2, p-ERK1/2, and p-AKT in SNU-1 cells were determined using Western blot analysis. To confirm that ERBB2 is a direct target of miR-133a, a… More >

  • Open Access

    ERRATUM

    MicroRNA-139-5p Inhibits Cell Proliferation and Invasion by Targeting RHO-Associated Coiled-Coil-Containing Protein Kinase 2 in Ovarian Cancer

    Yanli Wang*, Jia Li, Chunling Xu, Xiaomeng Zhang
    Oncology Research, Vol.28, No.7-8, pp. 823-825, 2020, DOI:10.3727/096504021X16240202940021
    Abstract Increasing evidence indicates that the dysregulation of microRNAs is associated with the development and progression of various cancers. MicroRNA-139-5p (miR-139-5p) has been reported to have a tumor suppressive role in many types of cancers. The role of miR-139-5p in ovarian cancer (OC) is poorly understood. The purpose of the present study was to explore the expression of miR-139-5p and its function in OC. The results showed that miR-139-5p expression was markedly downregulated in OC tissues and cell lines. In addition, underexpression of miR-139-5p was significantly associated with FIGO stage, lymph mode metastasis, and poor overall survival of OC patients. Functional… More >

  • Open Access

    ERRATUM

    Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells

    Dong Li*1, Fei-fan Sun*1, Dan Wang*1,Tao Wang*, Jing-jing Peng*, Jian-Qiong Feng*, Hua Li*, Chao Wang, Dai-jun Zhou*, Hong Luo*, Zeng-qiang Fu*, Tao Zhang*
    Oncology Research, Vol.28, No.7-8, pp. 827-828, 2020, DOI:10.3727/096504021X16280937554409
    Abstract Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immune evasion. Recently, it has been reported that PD-L1 could play crucial roles in drug resistance of many kinds of cancers. However, the expression, function, and regulation of PD-L1 in sorafenib-resistant hepatoma cells remain unclear. In this study, we reported that PD-L1 was overexpressed in sorafenib-resistant hepatoma cells, and shRNA-mediated PD-L1 depletion attenuated drug resistance and suppressed the migration,… More >

  • Open Access

    RETRACTION

    Retraction notice to “MicroRNA-98 Plays a Suppressive Role in Non-Small Cell Lung Cancer Through Inhibition of SALL4 Protein Expression” [Oncology Research 25(6) (2017) 975-988]

    Wenliang Liu*, Peng Xiao, Han Wu*, Li Wang*, Demiao Kong*, Fenglei Yu*
    Oncology Research, Vol.28, No.7-8, pp. 829-829, 2020, DOI:10.3727/096504021X16207253542097
    Abstract This article has no abstract. More >

  • Open Access

    RETRACTION

    Retraction notice to “MicroRNA-539 Inhibits the Epithelial-Mesenchymal Transition of Esophageal Cancer Cells by Twist-Related Protein 1-Mediated Modulation of Melanoma-Associated Antigen A4” [Oncology Research 26(4) (2018) 529-536]

    Zhili Cao*1, Xiang Zheng†1, Lei Cao*, Naixin Liang*
    Oncology Research, Vol.28, No.7-8, pp. 831-831, 2020, DOI:10.3727/096504020X16231418632584
    Abstract This article has no abstract. More >

  • Open Access

    RETRACTION

    Retraction notice to “High Blood miR-802 Is Associated With Poor Prognosis in HCC Patients by Regulating DNA Damage Response 1 (REDD 1)-Mediated Function of T Cells” [Oncology Research 27(9) (2019) 1025-1034]

    Chao Jiang*, Xueyan Liu, Meng Wang*, Guoyue Lv*, Guangyi Wang*
    Oncology Research, Vol.28, No.7-8, pp. 833-833, 2020, DOI:10.3727/096504018X16233193839045
    Abstract This article has no abstract. More >

  • Open Access

    RETRACTION

    MicroRNA-296 Targets Specificity Protein 1 to Suppress Cell Proliferation and Invasion in Cervical Cancer [Oncology Research 26(5) (2018) 775–783]

    Lili Lv*, Xiaodong Wang
    Oncology Research, Vol.28, No.7-8, pp. 835-835, 2020
    Abstract This article has no abstract. More >

Share Link

WeChat scan